{"entity":{"id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","aka":[],"tldr":"A phase 2 trial of Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib is a phase 2 interventional study registered as NCT06120140 by Janssen Research & Development, LLC, with 305 participants enrolled, started 2024-02-16 and due to reach its primary completion in 2027-05-31. Interventions recorded: Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline and Clindamycin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06120140","url":"https://clinicaltrials.gov/study/NCT06120140"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["amivantamab","lazertinib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06120140","phase":"2","setting":"A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib","sponsor":"Janssen Research & Development, LLC","enrolled":305,"outcomes":[]},"route":"/trials/nct06120140/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}